OPKO Health, Inc. (OPK)

Clinical laboratory and pharmaceuticals. Read November 11, 2026 from the annual report for the period ending December 31, 2025, filed February 26, 2026. Ranked 72 of the 145 Healthcare companies read so far, by the share within reach now.

A diagnostics and pharmaceutical company whose filing states its total and its laboratory business's count.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 33% now, 40% at the end of 2027, 42% at the end of 2028, 42% at the end of 2030. By the patterns, the work is about 42% desk work, 17% people work and 41% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 59% of the working time stays with people (conversation, in-person and hands-on work), 35% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

2,275 employees as of December 31, 2025 (stated). Not stated; one worldwide total.

The filing: “As of December 31, 2025, we had 2,275 full-time employees worldwide.”

The workforce as industry patterns

What the filing says about the workforce: The filing says the BioReference workforce is approximately 1,373 full-time employees, down from approximately 3,300 before its restructurings. A small number of employees in Spain are under a collective bargaining agreement.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Medical and Diagnostic Laboratories, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.

• Labcorp Holdings Inc. (LH, 71,000 employees)35% now, 45% by 2028
• Quest Diagnostics Incorporated (DGX, 57,000 employees)34% now, 41% by 2028
• RadNet, Inc. (RDNT, 11,264 employees)34% now, 41% by 2028
• Natera, Inc. (NTRA, 6,140 employees)34% now, 41% by 2028
• Lumexa Imaging Holdings, Inc. Common Stock (LMRI, 5,019 employees)34% now, 41% by 2028
• Tempus AI, Inc. (TEM, 3,800 employees)39% now, 51% by 2028
• Myriad Genetics, Inc. (MYGN, 2,700 employees)34% now, 41% by 2028
• Guardant Health, Inc. (GH, 2,506 employees)34% now, 41% by 2028

What the filing says about AI

5 sentences in the filing name AI. The filing names AI in risk factors: its use by threat actors in cyberattacks and the risks of flawed AI algorithms.

• “Such attacks also may be further enhanced in frequency or effectiveness through threat actors' use of artificial intelligence ("AI").”
• “As with many innovations, AI presents risks, challenges, and unintended consequences that could affect its adoption, and therefore our business.”
• “AI algorithms and training methodologies may be flawed, ineffective or inadequate.”
• “The rapid evolution of AI, particularly the anticipated government regulation of AI, could require significant resources for compliance, whether in the development, testing, or maintenance of such systems or software.”
• “AI development or deployment practices by us or third -party providers could increase vulnerability to cybersecurity risks and require additional resources to implement heightened cybersecurity measures to protect the security of our data.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20230median 1
• Fiscal 20240median 4
• Fiscal 20255median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The filing states full-time employees only.
• The pharmaceutical share is the remainder after the stated laboratory count.

Source: the company's annual report on EDGAR, accession 0001193125-26-076596, the filing. Read by Claude Fable 5.2 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.